ZYBT Stock Analysis

Zhengye Biotechnology Holding Limited • Veterinary Vaccines (China)

Data as of July 2026 • Nasdaq Capital Market
Key Finding: Zhengye Biotechnology Holding Limited (ZYBT) is a small Chinese veterinary vaccine producer that completed its Nasdaq IPO in January 2025, with its stock exhibiting extreme volatility (52-week range ~$0.62–$13.08), declining revenues (FY2025: ~$16.6M USD), ongoing losses, and a recent Nasdaq minimum bid price deficiency notice, while lacking meaningful analyst coverage.

Stock Performance & Company Financials

Stock Performance (Historical Context)

Data Limitation: Stock performance data reflects extreme post-IPO volatility typical of micro-cap listings; 52-week change of -87.73% as of mid-July 2026. YTD and 1-year returns show significant variance due to daily swings exceeding 300% in some instances. No dividends paid.
Metric Value Notes
52-Week Range $0.616 – $13.08 Fact: Post-IPO high reached shortly after listing; sharp declines followed.
52-Week Change -87.73% Fact vs. S&P 500 +18.27%
YTD Return ~+164% Interpretation: Highly volatile recovery from lows; subject to rapid reversals.
1-Year Return ~+46.6% Uncertainty: Period includes IPO and subsequent corrections.
Average Volume (3M) ~100,900 shares Fact; occasional volume spikes (e.g., >100M shares) during news events.

Links for more information:

Company Financials

Data Limitation & Assumptions: Financial figures primarily from FY2025 results (ended Dec 31, 2025) and TTM; currency conversions approximate (RMB to USD at historical rates). Revenue decline and losses are facts; future performance uncertain due to market conditions in China and compliance issues. Limited quarterly breakdowns publicly detailed.
Metric FY2025 FY2024 (Prior Year) TTM / Notes
Net Revenue RMB 116.4M (~US$16.6M) RMB 186.4M (~US$25.5M) 116.36M (Yahoo); ↓12–40% YoY depending on period
Gross Profit RMB 23.9M (~US$3.4M) RMB 91.3M Gross margin: 20.5% (vs 49% prior)
Net Income / EPS Significant loss — TTM Net Income: -69.78M; EPS: -0.22
Profit Margin — — -59.97%
Operating Margin — — -77.04%
Cash (mrq) — — US$51.89M
Total Debt (mrq) — — US$75.08M; Debt/Equity: 24.48%

Key Financial Highlights (Bullet Points):

Links for more information:

Analyst Ratings

Key Observation: No consensus analyst ratings, price targets, or earnings estimates available from major firms. This is common for recently listed micro-cap companies with limited institutional following.
Aspect Status Details
Number of Analysts 0 (or none covering) Fact: Multiple sources explicitly note absence of consensus estimates.
Price Target N/A —
Recommendation N/A —
Earnings Estimates None Fact: No forward EPS or revenue projections published.

Interpretation: Lack of coverage increases uncertainty for investors; stock movements driven primarily by news (e.g., Nasdaq notices) and retail trading rather than institutional analysis.

Links for more information:

Customers & Competitors

Customers

Data Limitation: Detailed customer concentration or contract information not publicly disclosed in detail; primarily B2B/government sales in China.

Competitors

Fact: Operates in Drug Manufacturers - Specialty & Generic / Animal Health segment. Direct public competitors in similar market cap range are limited; larger players exist globally in animal health.

Company Ticker Market Cap (approx.) Notes
Q/C Technologies QCLS $27M Similar small-cap pharma
Tvardi Therapeutics TVRD $30M Biotech peer
Veru Inc. VERU $38M Specialty pharma
Phibro Animal Health PAHC $1.35B Larger animal health competitor (for scale reference)
Other small biotechs UNCY, NGEN, etc. Varies Broader small-cap biotech peers

Links for more information:

Additional Context & Limitations: All information synthesized from publicly available sources as of July 2026. Company is an emerging growth company with VIE-like structure (Cayman holding with PRC operations). Recent Nasdaq compliance issues and financial deterioration introduce significant risks. Investors should review latest SEC filings (when available) and consult professional advisors. No current stock price displayed per guidelines.

Sources include: Yahoo Finance, PR Newswire/GlobeNewswire releases, SEC prospectus excerpts, TradingView, StockAnalysis, and others (specific citations available in tool results).